Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
US11918648B2 · kind B2 · utility
0Cited by
13References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 21, 2020 |
| Grant date | Mar 5, 2024 |
| Priority date | — |
| Expiry date | Aug 21, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.